[go: up one dir, main page]

AR072685A1 - Composicion topica para el tratamiento de queratosis actinica - Google Patents

Composicion topica para el tratamiento de queratosis actinica

Info

Publication number
AR072685A1
AR072685A1 ARP090102493A ARP090102493A AR072685A1 AR 072685 A1 AR072685 A1 AR 072685A1 AR P090102493 A ARP090102493 A AR P090102493A AR P090102493 A ARP090102493 A AR P090102493A AR 072685 A1 AR072685 A1 AR 072685A1
Authority
AR
Argentina
Prior art keywords
treatment
actinic keratosis
topical composition
active agent
keratosis
Prior art date
Application number
ARP090102493A
Other languages
English (en)
Inventor
Henning Mallwitz
Manfred Melzer
Carmen Matthies
Klaus Treudler
Christoph Willers
Original Assignee
Almirall Hermal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072685(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Hermal Gmbh filed Critical Almirall Hermal Gmbh
Publication of AR072685A1 publication Critical patent/AR072685A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion de gel topica que comprende (a) un agente activo para el tratamiento de queratosis actínica, como por ejemplo S'-fluorouracilo, (b) un agente queratolíticamente activo, como por ejemplo ácido salicílico, (c) un formador de gel y (d) un solvente orgánico para su uso en el tratamiento de queratosis actínica.
ARP090102493A 2008-07-07 2009-07-03 Composicion topica para el tratamiento de queratosis actinica AR072685A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
AR072685A1 true AR072685A1 (es) 2010-09-15

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102493A AR072685A1 (es) 2008-07-07 2009-07-03 Composicion topica para el tratamiento de queratosis actinica

Country Status (31)

Country Link
US (1) US8569320B2 (es)
EP (2) EP2143421A1 (es)
JP (2) JP5654987B2 (es)
KR (1) KR101689898B1 (es)
CN (2) CN102088957A (es)
AR (1) AR072685A1 (es)
AU (1) AU2009267471B2 (es)
BR (1) BRPI0915439B8 (es)
CA (1) CA2729974A1 (es)
CL (1) CL2010001642A1 (es)
CO (1) CO6351710A2 (es)
CY (1) CY1116111T1 (es)
DK (1) DK2315581T3 (es)
EA (1) EA019533B1 (es)
EC (1) ECSP11010762A (es)
ES (1) ES2532948T3 (es)
HR (1) HRP20150222T1 (es)
IL (1) IL210134A (es)
ME (1) ME02147B (es)
MX (1) MX2011000054A (es)
MY (1) MY158428A (es)
NZ (1) NZ590288A (es)
PE (1) PE20110330A1 (es)
PL (1) PL2315581T3 (es)
PT (1) PT2315581E (es)
RS (1) RS53887B1 (es)
SI (1) SI2315581T1 (es)
TW (1) TWI433692B (es)
UA (1) UA101044C2 (es)
WO (1) WO2010003568A1 (es)
ZA (1) ZA201100653B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004144A (es) * 2009-10-08 2012-05-08 Msd Consumer Care Inc Composicion de bajo contenido de eter y aparato de administracion.
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
WO2013088376A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited Gel compositions
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
BR112017001963A2 (pt) 2014-07-31 2017-11-21 Sun Pharmaceutical Ind Ltd composição farmacêutica oral, seu processo de preparação e método de tratamento
WO2016038035A1 (en) 2014-09-12 2016-03-17 Antibiotx Aps Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
FI3319637T3 (fi) * 2015-07-10 2023-02-22 Kaliumhydroksidin käyttö aktiinisen keratoosin hoitoon
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
CN110891575A (zh) 2017-03-10 2020-03-17 雅培克公司 治疗和/或预防光化性角化病的方法
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US20220175769A1 (en) * 2020-12-08 2022-06-09 Ankh Life Sciences Limited Method of treatment of actinic keratoses
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
HU0200901D0 (es) * 1996-06-20 2002-08-28 Lavipharm Sa
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
AU2005267396B2 (en) * 2004-06-24 2009-09-17 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
EP1890687B1 (en) * 2005-06-14 2008-09-17 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical gel of diclofenac sodium
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
CO6351710A2 (es) 2011-12-20
KR20110027838A (ko) 2011-03-16
HK1154793A1 (en) 2012-05-04
CA2729974A1 (en) 2010-01-14
IL210134A0 (en) 2011-02-28
JP5654987B2 (ja) 2015-01-14
TW201006507A (en) 2010-02-16
EP2143421A1 (en) 2010-01-13
SI2315581T1 (sl) 2015-05-29
AU2009267471B2 (en) 2014-06-05
BRPI0915439B8 (pt) 2021-05-25
BRPI0915439B1 (pt) 2019-10-08
RS53887B1 (sr) 2015-08-31
JP2011526934A (ja) 2011-10-20
KR101689898B1 (ko) 2016-12-26
EP2315581A1 (en) 2011-05-04
ME02147B (me) 2015-10-20
EA019533B1 (ru) 2014-04-30
CN102088957A (zh) 2011-06-08
HRP20150222T1 (hr) 2015-05-22
WO2010003568A8 (en) 2011-02-03
AU2009267471A1 (en) 2010-01-14
US20110301130A1 (en) 2011-12-08
EA201100020A1 (ru) 2011-06-30
ECSP11010762A (es) 2012-03-30
ZA201100653B (en) 2011-10-26
MX2011000054A (es) 2011-11-04
CY1116111T1 (el) 2017-02-08
MY158428A (en) 2016-10-14
WO2010003568A1 (en) 2010-01-14
NZ590288A (en) 2012-08-31
ES2532948T3 (es) 2015-04-06
TWI433692B (zh) 2014-04-11
DK2315581T3 (en) 2015-03-23
IL210134A (en) 2015-06-30
PE20110330A1 (es) 2011-06-11
JP2015038129A (ja) 2015-02-26
BRPI0915439A2 (pt) 2015-11-10
UA101044C2 (ru) 2013-02-25
US8569320B2 (en) 2013-10-29
CL2010001642A1 (es) 2011-04-08
PT2315581E (pt) 2015-04-02
CN104825384A (zh) 2015-08-12
PL2315581T3 (pl) 2015-06-30
EP2315581B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
BR112013018352A2 (pt) composição de minociclina tópica e método
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
MX353841B (es) Composiciones antimicrobianas y metodos de uso.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
ATE489048T1 (de) Vorrichtung für kombinierte behandlung
UY30759A1 (es) Compuestos quimicos
AR060165A1 (es) Proteina de suero como vehiculo de entrega para un agente activo
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
EA201071166A1 (ru) Контролируемое высвобождение активных агентов из олеосом
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
GT200600520A (es) Agentes antibacterianos
GB201105050D0 (en) Pharmaceutical agent
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure